Dramatic Response to Albendazole in Transplantation Candidates with Unresectable Hepatic Alveolar Hydatid Disease
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
Long-term albendazole treatment should be given to all patients with unresectable hepatic alveolar echinococcosis as dramatic regression is possible in 15%-20%. It may be prudent to prepare a living donor for possible salvage transplant in case of a severe complication. Preemptive transplantation in mildly symptomatic patients should be discouraged.
Citing Articles
Ocak S, Poyanli A, Gulluogu M, Ibis C, Tekant Y, Ozden I Clin Case Rep. 2021; 9(8):e04666.
PMID: 34457290 PMC: 8380084. DOI: 10.1002/ccr3.4666.
References
1.
Ozdemir F, Ince V, Barut B, Onur A, Kayaalp C, Yilmaz S
. Living donor liver transplantation for Echinococcus Alveolaris: single-center experience. Liver Transpl. 2015; 21(8):1091-5.
DOI: 10.1002/lt.24170.
View
2.
Bresson-Hadni S, Koch S, Beurton I, Vuitton D, Bartholomot B, Hrusovsky S
. Primary disease recurrence after liver transplantation for alveolar echinococcosis: long-term evaluation in 15 patients. Hepatology. 1999; 30(4):857-64.
DOI: 10.1002/hep.510300426.
View
3.
Ammann R, Stumpe K, Grimm F, Deplazes P, Huber S, Bertogg K
. Outcome after Discontinuing Long-Term Benzimidazole Treatment in 11 Patients with Non-resectable Alveolar Echinococcosis with Negative FDG-PET/CT and Anti-EmII/3-10 Serology. PLoS Negl Trop Dis. 2015; 9(9):e0003964.
PMC: 4577091.
DOI: 10.1371/journal.pntd.0003964.
View
4.
Polat K, Balik A, Celebi F
. Hepatic alveolar echinococcosis: clinical report from an endemic region. Can J Surg. 2002; 45(6):415-9.
PMC: 3684655.
View
5.
Brunetti E, Kern P, Vuitton D
. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop. 2009; 114(1):1-16.
DOI: 10.1016/j.actatropica.2009.11.001.
View